Form 4: Apogee Therapeutics CEO Michael Henderson Sells 15,000 Shares

Apogee Therapeutics CEO Michael Henderson sold 15,000 shares of common stock at an average price of $40.58 on February 5, 2025, according to a Form 4 filing.

Summary

• Michael Henderson, CEO of Apogee Therapeutics, sold 15,000 shares of common stock on February 5, 2025.
• The sale was executed at a weighted average price of $40.58 per share, with prices ranging from $40.30 to $40.92.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2023.
• Following the transaction, Henderson directly owns 1,302,987 shares of Apogee Therapeutics.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of a stock sale by the CEO under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like CEOs, buy or sell their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects. The use of a pre-arranged 10b5-1 trading plan suggests the sale was planned in advance to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale by the CEO could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Apogee Therapeutics, Michael Henderson, stock sale, Form 4, Rule 10b5-1, insider trading, APGE